Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Boehringer Ingelheim Pharmaceuticals |
---|---|
Information provided by: | Boehringer Ingelheim Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00273962 |
To compare the bronchodilator efficacy of ipratropium plus salbutamol (Combivent) with salbutamol alone given every 20 minutes for three doses in asthmatic children with severe acute exacerbation
Condition | Intervention | Phase |
---|---|---|
Asthma |
Drug: ipratropium plus salbutamol UDV Drug: salbutamol UDV |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Combivent UDV vs. Salbutamol UDV (2.5mg) for Treatment of an Acute Exacerbation of Asthma in Children |
Estimated Enrollment: | 490 |
Study Start Date: | May 2002 |
Estimated Study Completion Date: | November 2003 |
A Comparison of Ipratropium 500mcg and salbutamol 2.5mg (Combivent UDV) and salbutamol UDV alone (2.5mg) in a Double-blind, Efficacy and Safety Study in Asthmatic Children with Severe Acute Exacerbation
Study Hypothesis:
Several studies, including a study conducted in an emergency room setting, demonstrated that the addition of ipratropium bromide, an anticholinergic drug, to standard salbutamol therapy significantly improves pulmonary function as compared to salbutamol alone.
Comparison(s):
Ipratropium bromide 500 mcg plus salbutamol 2.5mg (Combivent) vs salbutamol (2.5mg) alone given every 20 minutes for 3 doses
Ages Eligible for Study: | 2 Years to 10 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA
EXCLUSION CRITERIA
Philippines | |
Philipines Heart Center | |
Quezon City, Philippines | |
San Juan de Dios Hospital | |
Pasay, Philippines | |
Philippine Children's Medical Center | |
Quezon, Philippines, 1104 | |
Philippine General Hospital | |
Manila, Philippines | |
Rizal Provincial Hospital | |
Pasig, Philippines | |
Quirino Memorial Medical Center | |
Quezon City, Philippines | |
Amang Rodriguez Hospital | |
Marikina, Philippines | |
Quezon City General Hospital | |
Quezon, Philippines | |
East Ave Medical Center | |
Quezon City, Philippines | |
Jose Reyes Memorial Medical Center | |
Manila, Philippines |
Study Chair: | Boehringer Ingelheim Study Coordinator | B.I. (Phil) Inc. |
Study ID Numbers: | 1012.45 |
Study First Received: | January 9, 2006 |
Last Updated: | March 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00273962 |
Health Authority: | Philippines: Bureau of Food and Drugs |
Hypersensitivity Lung Diseases, Obstructive Ipratropium Respiratory Tract Diseases Lung Diseases |
Albuterol Hypersensitivity, Immediate Asthma Respiratory Hypersensitivity |
Respiratory System Agents Neurotransmitter Agents Cholinergic Antagonists Molecular Mechanisms of Pharmacological Action Adrenergic Agents Bronchial Diseases Immune System Diseases Adrenergic beta-Agonists Physiological Effects of Drugs Anti-Asthmatic Agents |
Reproductive Control Agents Cholinergic Agents Adrenergic Agonists Pharmacologic Actions Tocolytic Agents Autonomic Agents Therapeutic Uses Peripheral Nervous System Agents Bronchodilator Agents |